Related Experiment Video
Updated: Jul 12, 2026
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
Félix Reyes1, Eric Lepage, Gérard Ganem
1Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France. felix.reyes@hmn.ap-hop-paris.fr
The New England Journal of Medicine
|March 25, 2005
Summary
For younger adults with low-risk localized lymphoma, chemotherapy alone using ACVBP is more effective than chemoradiotherapy with CHOP. This approach significantly improves event-free and overall survival rates.
Area of Science:
- Oncology
- Clinical Trials
- Lymphoma Treatment
Background:
- Chemoradiotherapy is a standard treatment for localized aggressive lymphoma.
- Optimal therapy for non-elderly patients with low-risk localized lymphoma requires investigation.
Purpose of the Study:
- To compare chemoradiotherapy with chemotherapy alone for treating low-risk localized aggressive lymphoma in patients under 61.
- To determine the superior treatment regimen for improved survival outcomes.
Main Methods:
- A randomized trial compared three cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radiotherapy versus dose-intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus consolidation.
- Patients were under 61 years old with localized stage I or II aggressive lymphoma and no adverse prognostic factors.
Main Results:
- Chemotherapy alone (ACVBP) demonstrated significantly higher event-free survival (82% vs. 74% at 5 years) and overall survival (90% vs. 81% at 5 years) compared to CHOP plus radiotherapy.
- Treatment group significantly impacted survival rates, independent of tumor stage or bulky disease presence.
Conclusions:
- For patients under 61 with low-risk localized lymphoma, ACVBP chemotherapy with consolidation is superior to CHOP plus radiotherapy.
- This finding supports chemotherapy alone as an optimal treatment strategy for this patient group.
